Karyopharm's SENTRY Trial: Myelofibrosis Breakthrough Unveiled
Navigating the Latest Data: Karyopharm’s SENTRY Trial and What it Means for Your Portfolio Hey everyone, Sarah Miller here. It’s been a busy week in the markets, and I’ve been digging into some interesting developments, especially in the biotech space. You know me, I love keeping a pulse on innovative companies that are pushing the boundaries. Today, I want to chat about Karyopharm Therapeutics Inc. (KPTI) and their recent discussion of the topline results from their Phase III SENTRY trial in myelofibrosis. ...